Would you offer adjuvant chemotherapy, osimertinib, or both to a patient with Stage IB EGFR mutated lung adenocarcinoma found in the lung explant pathology after bilateral lung transplant?   

Would you consider the immune suppressed status of the patient as a high risk factor to offer adjuvant therapy?

Answer from: Medical Oncologist at Academic Institution